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Abstract
Introduction: HIV treatment guidelines now recommend antiretroviral therapy (ART) initiation regardless of CD4 count to
maximize benefit both for the individual and society. It is unknown whether the initiation of ART at higher CD4 counts would
affect adherence levels. We investigated whether initiating ART at higher CD4 counts was associated with sub-optimal adher-
ence (<95%) during the first 12 months of ART.
Methods: A prospective cohort study nested within a two-arm cluster-randomized trial of universal test and treat was imple-
mented from March 2012 to June 2016 to measure the impact of ART on HIV incidence in rural KwaZulu-Natal. ART was ini-
tiated regardless of CD4 count in the intervention arm and according to national guidelines in the control arm. ART
adherence was measured monthly using a visual analogue scale (VAS) and pill counts (PC). HIV viral load was measured at
ART initiation, three and six months, and six-monthly thereafter. We pooled data from participants in both arms and used ran-
dom-effects logistic regression models to examine the association between CD4 count at ART initiation and sub-optimal adher-
ence, and assessed if adherence levels were associated with virological suppression.
Results: Among 900 individuals who initiated ART ≥12 months before study end, median (IQR) CD4 at ART initiation was
350 cells/mm3 (234, 503); median age was 34.6 years (IQR 27.4 to 46.4) and 71.7% were female. Adherence was sub-optimal
in 14.7% of visits as measured by VAS and 20.7% by PC. In both the crude analyses and after adjusting for potential con-
founders, adherence was not significantly associated with CD4 count at ART initiation (adjusted OR for linear trend in sub-
optimal adherence with every 100 cells/mm3 increase in CD4 count: 1.00, 95% CI 0.95 to 1.05, for VAS, and 1.03, 95% CI
0.99 to 1.07, for PC). Virological suppression at 12 months was 97%. Optimal adherence by both measures was significantly
associated with virological suppression (p < 0.001 for VAS; p = 0.006 for PC).
Conclusions: We found no evidence that higher CD4 counts at ART initiation were associated with sub-optimal ART adher-
ence in the first 12 months. Our findings should alleviate concerns about adherence in individuals initiating ART at higher
CD4 counts, however long-term outcomes are needed. ClinicalTrials.gov NCT01509508.
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1 | INTRODUCTION
The most recent WHO antiretroviral therapy (ART) guidelines
recommend ART initiation regardless of CD4 count [1] based
on the findings from two randomized trials of early ART initia-
tion [2,3]. This has now been adopted by South Africa [4], the
country with the biggest HIV burden and treatment pro-
gramme globally. Currently, there is a lack of good quality data
on ART adherence at high CD4 counts (CD > 350 cells/mm3)
in the African setting. In the TEMPRANO trial conducted in
Ivory Coast, virological suppression 12 months post-ART initi-
ation was achieved in 84% and 80% in the immediate
(CD4 ≤ 800 cells/mm3) and deferred ART (initially
CD4 < 200 cells/mm3 until 2013, then 500 cells/mm3 after-
wards) arm, respectively [2]. These findings would suggest that
adherence levels were equal in both groups, although
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adherence was not reported in the trial. Findings from two of
three studies in the African setting that compared adherence
in individuals initiating ART at high CD4 count with those initi-
ating at lower CD4 counts were contradictory [5,6]. Further-
more, these two studies evaluated adherence in patients who
were on an ART regimen based mainly on a thymidine ana-
logue backbone (zidovudine or stavudine), known to be less
tolerable than tenofovir-based regimens [7].
ART adherence is critical in order to achieve the third 90
of the UNAIDS 90-90-90 target: 90% of all people living
with HIV being diagnosed, 90% of diagnosed individuals
being on ART, and 90% of those on ART being virologically
suppressed [8]. However, concern has been expressed that
individuals offered ART at higher CD4 counts, with relatively
preserved immune function, may not be motivated to adhere
to ART as most would be asymptomatic and healthy, hence
may not perceive ART to be of immediate benefit to their
own health. This could be the case especially in low income
settings where people often have competing beliefs about
medication taking as well as priorities around economic
resources [9].
In this paper, we examine ART adherence in a nested cohort
study within the ANRS Treatment as Prevention Trial. The
strength of this design is that individuals initiated ART based
on the initiation criteria assigned to the cluster in which they
were resident rather than self-selecting when to start ART.
We hypothesized that individuals initiating ART at higher
CD4 counts would be more likely to have sub-optimal adher-
ence than individuals initiating ART at lower CD4 counts. We
quantified adherence using two different adherence measure-
ment tools. We examined whether CD4 count at ART initia-
tion was associated with sub-optimal adherence during the
first 12 months of ART and assessed which measures of
adherence adequately predicted virological suppression at
12 months.
2 | METHODS
2.1 | Ethics statement
The main trial was approved by the Biomedical Research
Ethics Committee (BFC 104/11) of the University of Kwa-
Zulu-Natal and the Medicines Control Council of South Africa.
(ClinicalTrials.gov: NCT01509508; South African National
Clinical Trials Register: DOH-27-0512-3974). The nested
cohort study received additional approval from University Col-
lege London Research Ethics Committee (Project ID: 6604/
001). All participants provided written or witnessed thumb-
print informed consent.
2.2 | Study design and participants
The investigations were conducted within a prospective
cohort study nested within a cluster-randomized trial imple-
mented in 22 clusters (2 9 11) from March 2012 to June
2016 to investigate the impact of ART on population HIV inci-
dence in the Hlabisa sub-district in rural KwaZulu-Natal [10].
This is a rural setting with scattered homesteads and an esti-
mated HIV prevalence of 30.5% [11]. Control arm participants
were offered ART according to the South African guidelines
(CD4 count ≤350 at trial start, then CD4 count ≤500 from
January 2015). Those in the intervention arm were offered
ART regardless of CD4 count. The trial protocol has been
described previously [12]. In this cohort study, sub-optimal
adherence was examined according to CD4 count at ART initi-
ation, irrespective of arm in trial. Individuals were eligible for
inclusion in the cohort if aged ≥16 years, and had initiated
ART at least 12 months prior to database closure on 30 June
2016.
2.3 | Procedures
Six-monthly home-based HIV counselling and testing (HCT)
using rapid test technology was offered to resident members
of the trial communities using a serial testing algorithm [13].
Individuals identified HIV positive were referred to trial clin-
ics located in each of the 22 clusters. HIV-positive partici-
pants enrolled in trial clinics were asked to provide written
consent to complete case report forms and provide blood
specimens for viral load (VL) testing. ART was offered
according to cluster allocation. All participants had point-of-
care CD4 measurement (Alere Pima CD4 test, Alere, Wal-
tham, MA, US); those eligible for ART attended adherence
and ART literacy sessions and were offered ART within two
weeks of the baseline visit, or sooner if severely immuno-
compromised. The single tablet regimen, Atripla (comprising
tenofovir, emtricitabine & efavirenz) was used for first-line
ART, except if clinically contraindicated such as in renal dis-
ease. Second-line ART was informed by the results of geno-
typic resistance tests in participants failing first-line ART
(VL > 1000 copies/ml measured three months apart after
≥six months on ART).
Participants receiving ART were evaluated monthly for
adherence measurement and ART prescription. Scheduled
safety monitoring of blood (urea, electrolytes, creatinine, liver
function tests, full blood count) and HIV VL measurements
(Abbott m2000 RealTime System, Abbott Molecular, Des
Plaines, IL, US) occurred at the first visit, three and six months
after ART initiation, and every 6 months thereafter. Partici-
pants were also encouraged to attend the clinic at unsched-
uled visits if they had clinical complaints. Patients not yet
eligible for ART in the control clusters were asked to return
to the study clinic in four to six months for reassessment of
ART eligibility. A participant missing a clinic appointment was
contacted by telephone, and, when possible, a new appoint-
ment was scheduled. Those not contacted by phone were fol-
lowed up with home visits carried out by trackers. Participants
who did not attend within 90 days of their last clinic appoint-
ment and who could not be contacted were considered lost to
follow-up.
2.4 | Definition of outcome and exposure variables
Adherence was measured using both a visual analogue scale
(VAS) and pill counts (PC) at each scheduled visit.
The VAS was represented by a horizontal line with ends at
0 and 100. Participants were asked to put a mark on the scale
which best reflected their adherence in the previous four
days. Adherence was categorized as sub-optimal if the VAS
was <95%.
PC adherence was calculated [(N tablets issued  N tablets
returned)/N tablets expected to have been taken]*100.
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Adherence was considered sub-optimal if PC adherence was
<95% or >105%.
CD4 cell count at ART initiation was the primary exposure
variable.
2.5 | Statistical analysis
Baseline characteristics were tabulated by sex.
Adherence at each visit was plotted over the first
12 months after ART initiation; during this period, adherence
was expected to be documented at 14 visits (2, 4, 8, 12, 16,
20, 24, 28, 32, 36, 40, 44, 48, 52 weeks post-ART initiation)
for those who remained in the trial for the 12 months. The
number of expected visits was lower among those who exited
the trial earlier than 12 months.
Random effects logistic regression was used to examine the
association between CD4 count at initiation and sub-optimal
adherence at each visit. All models included a priori an indica-
tor for trial arm, a fixed effect for time since ART start, a ran-
dom coefficient (slope) for time at the individual level, and
random intercepts at both the clinic and the individual-within-
clinic levels.
CD4 count at ART initiation was analysed as a continuous
covariate. In order to allow for non-linear relationships
between CD4 count and adherence, we used fractional polyno-
mial (FP) functions [14]. Fractional polynomials provide a flexi-
ble way to model the shape of the relationship of a continuous
variable with the outcome. We used a set of defined powers
(2, 1, 0.5, 0.5, 1, 2 and ln(x)) and a maximum of two
power terms in the model. The differences in model deviances
were compared; the linear model was used if the improvement
in fit was not statistically significant at p < 0.05. Time in trial
and age at ART initiation were handled in a similar manner.
Other continuous exposure variables (distance to clinic, self-
reported health status) were categorized, a priori, into binary
variables above and below their median values. We used the
validated Patient Health Questionnaire (PHQ4) scale published
in the literature for screening of depression [15].
In the final multivariable analysis, we adjusted for potential
confounders commonly cited in the literature [16,17]. We
tested for interactions between CD4 count and trial arm,
CD4 count and time in trial, and CD4 count and sex, to assess
whether the effect of CD4 count on adherence depended on
trial arm, time or on sex. Likelihood ratio tests were used to
derive p-values.
We also assessed whether mean VAS or PC score in each
individual during the first 12 months of ART was associated
with virological suppression at 12 months. Participants were
considered to be virologically suppressed if their viral load
was below 400 copies/ml; the viral load measurement taken
closest to the 12-month time point, within a three-month
window, was used for the assessment. Mean adherence scores
were calculated for each participant by taking the mean of the
observed adherence scores at each visit. Adherence measures
were classified into three (VAS) and four (PC) categories to
explore relationship with virological suppression. As a sensitiv-
ity analysis, we examined the association of mean adherence
during the first six months on ART with virological suppression
at six months.
All statistical analyses were undertaken using Stata 15 (Sta-
taCorp LLC, College Station, Texas 77845, USA).
3 | RESULTS
3.1 | Cohort characteristics
A total of 1547 ART-na€ıve (self-reported never being on ART)
individuals were enrolled in trial clinics, of whom 1198 initi-
ated ART. Of the 926 who initiated ART at least 12 months
before database closure, 900 had at least one adherence mea-
surement (VAS or Pill count) during the 12-month period and
were included in the analyses (Figure 1).
Figure 1. Flow chart of cohort.
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Of the 900 individuals who were included in the analysis,
72% were female. Median age was 34.6 (IQR 27.4 to 49.5);
females were younger than males (median 33.3 years vs.
36.7 years, respectively). Educational attainment was low, with
42% of women and 45% of men having only primary educa-
tion. A large proportion of the population was unemployed
(84% women vs. 73% men). The median CD4 count at ART
initiation was 350 (IQR 234 to 503) (Table 1).
3.2 | Comparison of adherence measurements
Of the 7945 visits where participants had both VAS and PC
measurements, the two measurements were concordant in
6493 (81.7%) of visits, with adherence classified as optimum
according to both measures in 73.5% of visits, and suboptimal
in 8.2% of visits. VAS and PC were discordant in 18.3% of vis-
its; adherence was optimal on PC but sub-optimal on VAS in
Table 1. Characteristics of individuals included in the analysis during the first 12 months’ adherence analysis using visual analogue
scale and pill count
Female
N = 645 (71.7%)
n (% of N)
Male
N = 255 (28.3%)
n (% of N)
Total
N = 900
Clinical characteristics
CD4 at initiation Median (IQR) 374 (254, 525) 311 (205, 451) 350 (234, 503)
≤350 295 (45.7) 154 (60.4) 449 (49.9)
350 to 500 166 (25.7) 56 (22.0) 222 (24.7)
>500 181 (28.1) 45 (17.7) 226 (25.1)
Missing 3 (0.5) 0 (0.0) 3 (0.3)
Viral Load at first clinic visit (Log10 copies/ml)
Median (IQR) 4.4 (3.8, 5.1) 4.8 (4.1, 5.4) 4.5 (3.8, 5.2)
Age at initiation (years)
Median age (IQR) 33.3 (26.0, 45.0) 36.7 (29.9, 49.5) 34.6 (27.4,46.4)
16 to 29 254 (39.4) 66 (25.9) 320 (35.6)
30 to 39 170 (26.6) 82 (32.2) 252 (28.0)
40 to 49 108 (16.7) 45 (17.7) 153 (17.0)
>50 112 (17.4) 62 (24.3) 174 (19.3)
Missing 1 (0.2) 0 (0.0) 1 (0.1)
Educational attainment
Primary or less 274 (42.5) 116 (45.5) 390 (43.3)
Some secondary 344 (53.3) 127 (49.8) 471 (52.3)
Completed secondary or higher 23 (3.6) 12 (4.7) 35 (3.9)
Missing 4 (0.6) 0 (0.0) 4 (0.4)
Marital status
Never married 564 (87.4) 215 (84.3) 779 (86.6)
Married 45 (7.0) 33 (12.9) 78 (8.7)
Divorced/separated 33 (5.1) 7 (2.8) 40 (4.4)
Missing 3 (0.5) 0 (0.0) 3 (0.3)
Employment status
Employed 75 (11.6) 62 (24.3) 137 (15.2)
Student 29 (4.5) 6 (2.4) 35 (3.9)
Unemployed 540 (83.7) 186 (72.9) 726 (80.7)
Missing 1 (0.2) 1 (0.4) 2 (0.2)
Trial arm
Intervention 278 (43.1) 110 (43.1) 388 (43.1)
Control 367 (56.9) 145 (56.9) 512 (56.9)
Food insecurity
Yes 420 (65.1) 149 (58.4) 569 (63.2)
No 210 (32.6) 101 (39.6) 311 (34.6)
Do not know 6 (0.9) 4 (1.6) 10 (1.1)
Missing 9 (1.4) 1 (0.4) 10 (1.1)
IQR, interquartile range.
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Table 2. Association between CD4 count at initiation and other factors with <95% visual analogue scale adherence during the first
12 months of ART
Characteristics
Adherence <95%
N visits/total visits
¥Crude odds
ratio (95% CI) p value
&Adjusted odds
ratio (95% CI) p value
CD4 at Initiation (cells/mm3) n = 8866
≤350 679/4432 (15.3)
350 to 500 318/2231 (14.3) 0.97 (0.93 to 1.02)a 0.204 1.00 (0.95 to 1.05)a 0.963
>500 308/2203 (14.0)
Age at initiation n = 8864
16 to 29 476/2847 (16.7)
30 to 39 355/2520 (14.1) 1.01 (0.97 to 1.05)b 0.625 0.98 (0.93 to 1.04)b 0.464
40 to 49 222/1654 (13.4)
>50 255/1843 (13.8)
Sex n = 8874 <0.0001 <0.0001
Female 811/6500 (12.5) 1 1
Male 497/2374 (20.9) 2.21 (1.76 to 2.77) 2.29 (1.80 to 2.90)
Education n = 8830 0.983
Primary or less 563/4045 (13.9) 1 1
Some secondary 693/4441 (15.6) 1.01 (0.81 to 1.26) 1.00 (0.76 to 1.30)
At least completed secondary 46/344 (13.4) 0.92 (0.51 to 1.65) 0.94 (0.51 to 1.75)
Marital status n = 8841 0.417 0.303
Never been married 1150/7616 (15.1) 1 1
Married 106/818 (13.0) 0.90 (0.60 to 1.33) 0.73 (0.48 to 1.12)
Divorced/separated 46/407 (11.3) 0.71 (0.41 to 1.22) 0.79 (0.45 to 1.39)
Employment status n = 8852 0.743 0.810
Employed 217/1396 (15.5) 1 1
Student 54/309 (17.5) 1.02 (0.55 to 1.89) 1.23 (0.65 to 2.33)
Unemployed 1033/7147 (14.5) 0.90 (0.67 to 1.21) 1.03 (0.77 to 1.39)
First line Regimen n = 8835 <0.0001 0.0005
Separate tablet regimen 91/382 (23.8) 1 1
Single tablet regimen 1204/8453 (14.2) 0.72 (0.61 to 0.85) 0.40 (0.24 to 0.67)
ART treatment perception
Agree that ART will improve health n = 8760 0.854 0.641
Yes 1227/8395 (14.6) 1 1
No 22/128 (17.2) 1.20 (0.52 to 2.79) 1.22 (0.49 to 3.01)
Do not know 40/237 (16.9) 1.14 (0.59 to 2.21) 1.41 (0.65 to 3.04)
Worried about side effects of ART n = 8703 0.599 0.859
Yes 1075/7409 (14.5) 1 1
No 65/433 (15.0) 1.08 (0.65 to 1.80) 0.96 (0.54 to 1.69)
Do not know 138/861 (16.0) 0.84 (0.57 to 1.22) 0.89 (0.60 to 1.33)
Agree that ART will reduce transmission n = 8626 0.193 – –
Yes 889/6627 (13.4) 1
No 120/705 (17.0) 1.37 (0.91 to 2.06)
Do not know 245/1294 (18.9) 1.26 (0.90 to 1.77)
HIV status disclosure to anyone n = 8739 0.891 0.368
Yes 1108/7485 (14.8) 1 1
No 189/1254 (15.1) 0.98 (0.72 to 1.34) 0.86 (0.63 to 1.19)
HIV status disclosure to current partner n = 8574 0.05 – –
Yes 724/4739 (15.3) 1
No partner disclosure 351/2487 (14.1) 0.84 (0.66 to 1.08)
No partner 195/1348 (14.5) 0.91 (0.67 to 1.24)
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5.8% of visits, and sub-optimal on PC but optimal on VAS in
12.5% of visits.
3.3 | Association between CD4 count at initiation
and visual analogue scale adherence <95% during the
first 12 months
The 900 participants had 8874 (77.1%) visits with VAS adher-
ence measurements, of the 11,507 expected visits in the 12-
month period. VAS adherence was optimal (≥95%) in 7566
(85.3%) of these 8874 visits (Figure S1). The median number
of visits per individual was 11 (IQR 10 to 12).
In the crude analysis, and after adjusting for potential con-
founders, there was no evidence of an association between
CD4 count at ART initiation and sub-optimal VAS adherence
during the first 12 months on ART (adjusted (a)OR for linear
trend in sub-optimal adherence with every 100 cells/mm3
increase in CD4 count = 1.00, 95% CI 0.95 to 1.05,
p = 0.96; Table 2). The results of the FP models showed that
the linear model adequately described the relationship
between CD4 count and VAS adherence. There was no evi-
dence that the effect of CD4 count on VAS adherence
differed between trial arms, between men and women, or
with time in the trial (p-values for interaction = 0.06, 0.17,
and 0.29, respectively).
In the final model, there was strong evidence of an associa-
tion of male sex with sub-optimal VAS adherence (aOR 2.29,
95% CI 1.80 to 2.90, p < 0.001). Being on a single tablet ART
regimen was associated with a lower odds of sub-optimal
adherence (aOR 0.40, 95% CI 0.24 to 0.67, compared with
those on separate tablet regimen; p < 0.001). In addition,
there was some evidence that individuals who did not have
food insecurity were less likely to have sub-optimal adherence
(aOR 0.76, 95% CI 0.60 to 0.97, p = 0.06). There was no evi-
dence of association of time on ART (p = 0.54), or of trial arm
(p = 0.51), with sub-optimal adherence as measured by VAS.
3.4 | Association between CD4 count at initiation
and sub-optimal pill count adherence during the first
12 months
Of the 900 participants in the current study, four had no pill
count adherence measurements. The 896 participants had PC
adherence measurements at 8014 (69.8%) of the 11,475
Table 2. (Continued)
Characteristics
Adherence <95%
N visits/total visits
¥Crude odds
ratio (95% CI) p value
&Adjusted odds
ratio (95% CI) p value
Food insecurity n = 8783 0.639 0.057
Yes 912/5668 (16.1) 1 1
No 377/3025 (12.5) 0.89 (0.71 to 1.14) 0.76 (0.60 to 0.97)
Do not know 10/90 (11.1) 0.84 (0.27 to 2.61) 2.95 (0.21 to 41.94)
Psychological distress (PHQ4) n = 8597 0.547 –
None 997/7023 (14.2) 1 –
Mild 244/1337 (17.7) 1.11 (0.79 to 1.56)
Moderate 18/103 (17.5) 1.34 (0.52 to 3.39)
Severe 21/94 (22.3) 1.86 (0.70 to 4.95)
Self to reported health status n = 8863 0.535 0.975
≤80 801/5474 (14.6) 1 1
>80 506/3389 (14.9) 0.93 (0.74 to 1.17) 1.00 (0.79 to 1.27)
Distance from home to trial clinic (km) n = 8874 0.804 0.607
≤1.3 683/4433 (15.4) 1 1
>1.3 625/4441 (14.1) 1.03 (0.82 to 1.29) 0.94 (0.75 to 1.18)
Time in study (months) n = 8874
≤6 711/4927 (14.4) 1.01 (0.99 to 1.03) 0.284 1.01 (0.98 to 1.03)c 0.536
>6 597/3947 (15.1)
Trial arm n = 8874 0.452 0.506
Control 617/3852 (16.0) 1 1
Intervention 691/5022 (13.8) 0.79 (0.43 to 1.45) 0.82 (0.45 to 1.49)
¥ORs estimated from random effects logistic regression, with a fixed effect for time, a random coefficient for time at the individual level, and random
intercepts at both the cluster and the individual-within-cluster level. &adjusted for age, sex, marital status, employment, whether on fixed dose combi-
nation of ART, food insecurity, distance to clinic, worried about side-effects, agree that ART will improve health, status disclosure to anyone and self-
reported health status and trial arm. aOdds ratio for linear trend in sub-optimal adherence with every 100-unit increase in CD4 count at initiation.
bOdds ratio for linear trend in sub-optimal adherence with every 5-year increase in age. cOdds ratio for linear trend in sub-optimal adherence with
every month on ART. Distance to the nearest TasP clinic: obtained by measuring the distance as the crow flies from the participant’s home (GPS
coordinates) to the trial clinic (GPS coordinates) in their cluster. Depression (assessed using the Patient Health Questionnaire (PHQ)-4 scale rated as
normal (0 to 2), mild (3 to 5), moderate (6 to 8) and severe (9 to 12), [15]. Self-reported health status (as measured using a scale ranging from 0 to
100% in which 0 represents poor health and 100% represents excellent health). Food insecurity (as measured by whether skipped meals in last
12 months or not). ART treatment perception (through three questions concerning the participant’s attitudes about ART).
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Table 3. Association between CD4 count at initiation and sub-optimal pill count adherence during the first 12 months of ART
Characteristics
Adherence <95%/>105
N visits/total visits
¥Crude odds
ratio (95% CI) p value
&Adjusted odds
ratio (95% CI) p value
CD4 at initiation (cells/mm3) n = 8006
350 851/4016 (21.2)
350 to 500 400/2009 (19.9) 1.00 (0.96 to 1.03)a 0.830 1.03 (0.99 to 1.07)a 0.205
>500 407/1981 (20.6)
Age at initiation n = 8005
16 to 29 580/2559 (22.7)
30 to 39 464/2313 (20.1) 0.99 (0.96 to 1.03)b 0.632 0.96 (0.91 to 1.01)b 0.085
40 to 49 286/1482 (19.3)
>50 330/1651 (20.0)
Sex n = 8014 <0.0001 <0.0001
Female 1057/5962 (17.7) 1 1
Male 605/2052 (29.5) 2.23 (1.83 to 2.71) 2.41 (1.95 to 2.97)
Educational attainment n = 7972 0.469 0.218
Primary or less 732/3682 (19.9) 1 1
Some secondary 868/3974 (21.8) 1.06 (0.87 to 1.29) 0.98 (0.77 to 1.24)
At least completed secondary 51/316 (16.1) 0.78 (0.47 to 1.31) 0.62 (0.35 to 1.08)
Marital status n = 7983 0.886 0.543
Never been married 1435/6872 (20.9) 1 1
Married 142/753 (18.9) 0.93 (0.67 to 1.30) 0.87 (0.61 to 1.25)
Divorced/separated 74/358 (20.7) 0.93 (0.59 to 1.48) 1.17 (0.73 to 1.88)
Employment status n = 7992 0.391 0.956
Employed 297/1258 (23.6) 1 1
Student 56/274 (20.4) 0.97 (0.56 to 1.69) 1.01 (0.57 to 1.80)
Unemployed 1300/6460 (20.1) 0.84 (0.65 to 1.09) 0.97 (0.75 to 1.25)
First line regimen n = 7977 0.013 0.019
Separate tablet regimen 74/285 (26.0) 1 1
Single tablet regimen 1581/7692 (20.6) 0.82 (0.70 to 0.96) 0.56 (0.34 to 0.90)
ART treatment perception
Agree that ART will improve health n = 7908 0.589 0.499
Yes 1567/7569 (20.7) 1 1
No 29/111 (26.1) 1.44 (0.68 to 3.03) 1.61 (0.73 to 3.54)
Do not know 51/228 (22.4) 1.13 (0.64 to 1.98) 1.09 (0.56 to 2.15)
Worried about side effects of ART n = 7858 0.779 0.202
Yes 1383/6644 (20.8) 1 1
No 74/400 (18.5) 0.94 (0.60 to 1.48) 0.69 (0.42 to 1.13)
Do not know 178/814 (21.9) 1.11 (0.80 to 1.54) 1.15 (0.81 to 1.63)
Agree that ART will reduce transmission n = 7781 0.778 – –
Yes 1225/5922 (20.7) 1
No 132/646 (20.4) 1.13 (0.78 to 1.62)
Do not know 256/1213 (21.1) 1.07 (0.80 to 1.43)
HIV status disclosure to anyone n = 7888 0.247 0.603
Yes 1386/6752 (20.5) 1 1
No 259/1136 (22.8) 1.17 (0.90 to 1.54) 1.08 (0.82 to 1.42)
HIV status disclosure to current partner n = 7743
Yes 893/4277 (20.9) 1 –
No 450/2240 (20.1) 0.91 (0.73 to 1.13)
Not applicable (No partner) 272/1226 (22.2) 1.10 (0.84 to 1.45)
Food Insecurity n = 7035 0.860 0.440
Yes 1076/5090 (21.1) 1 1
No 561/2764 (20.3) 1.02 (0.83 to 1.25) 0.87 (0.71 to 1.07)
Do not know 14/81 (17.3) 0.78 (0.30 to 2.01) 0.99 (0.09 to 11.43)
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expected visits in the 12-month period. PC adherence was
optimal in 6352 (79.3%) of these visits, and was >105% in
5.9% of visits (Figure S2). The median number of visits with
PC adherence data per individual was 11 (IQR 9 to 12).
In the crude analysis, and after adjusting for potential con-
founders, there was no evidence of an association between
CD4 count at ART initiation and sub-optimal adherence as
measured by PC during the first 12 months on ART (aOR
for linear trend in sub-optimal adherence with every
100 cells/mm3 increase in CD4 count = 1.03, 95% CI 0.99
to 1.07, p = 0.21). The results of the FP models showed that
the linear model adequately described the relationship
between CD4 count and PC adherence. There was no evi-
dence that the effect of CD4 count on PC adherence dif-
fered between trial arms, between men and women, or with
time in the trial (p-values for interaction = 0.26, 0.09, and
0.22, respectively).
In the final model, as with VAS adherence, there was strong
evidence of an association of male sex with sub-optimal PC
adherence. Similarly, being on a single tablet ART regimen was
associated with a lower odds of sub-optimal adherence. Unlike
with VAS adherence, there was strong evidence that sub-opti-
mal PC adherence increased with increasing time on ART
(aOR for linear trend in sub-optimal adherence with every
month on ART = 1.04, 95% CI 1.02 to 1.06, p < 0.001).
However, there was no evidence of an association with trial
arm (p = 0.17) (Table 3).
3.5 | Relationship between adherence and
virological suppression at 12 months
Of 664 individuals with viral load data at 12 months, 644
(97%) achieved virological suppression. Of the 568 indi-
viduals with mean VAS adherence ≥95%, 557 (98%)
achieved virological suppression at 12 months compared
to 86/94 (91%) in those with <95% adherence (p < 0.001;
Figure 2). When adherence was measured by PC, optimal
adherence (95 to 105%) was also predictive of higher
odds of virological suppression (98%) compared to those
with lower levels of adherence (Figure 2). Of note, only
83% with adherence ≥105% as measured by PC achieved
virological suppression at 12 months. Similar patterns
were seen with virological suppression at six months
(Figure S3).
4 | DISCUSSION
In this cohort analysis of participants enrolled in a cluster ran-
domized trial, the majority of whom were female, we found no
Table 3. (Continued)
Characteristics
Adherence <95%/>105
N visits/total visits
¥Crude odds
ratio (95% CI) p value
&Adjusted odds
ratio (95% CI) p value
Psychological distress (PHQ4) n = 7758 0.108
None 1301/6432 (20.2) 1
Mild 281/1147 (24.5) 0.91 (0.67 to 1.23) – –
Moderate 19/94 (20.2) 1.07 (0.46 to 2.47)
Severe 27/85 (31.8) 2.84 (1.20 to 6.74)
Self to reported health status n = 8003 0.916 0.843
≤80 1004/4917 (20.4) 1 1
>80 653/3086 (21.2) 1.01 (0.83 to 1.23) 1.02 (0.83 to 1.26)
Distance from home to trial clinic (Km) n = 8014 0.634 0.396
≤1.3 864/3923 (22.0) 1 1
>1.3 798/4091 (19.5) 0.95 (0.78 to 1.16) 0.92 (0.75 to 1.12)
Time (months) n = 8007
≤6 854/4494 (19.0) 1.04 (1.02 to 1.06) <0.001 1.04 (1.02 to 1.06)c <0.001
>6 805/3513 (22.9)
Trial arm n = 8014 0.246 0.173
Control 779/3384 (23.0) 1 1
Intervention 883/4630 (19.1) 0.77 (0.49 to 1.20) 0.74 (0.48 to 1.13)
¥ORs estimated from random effects logistic regression, with a fixed effect for time, a random coefficient for time at the individual level, and ran-
dom intercepts at both the cluster and the individual-within-cluster level. &adjusted for age, sex, marital status, employment, whether on fixed
dose combination of ART, food insecurity, distance to clinic, worried about side-effects, agree that ART will improve health, status disclosure to
anyone and self-reported health status and trial arm. *Odds ratio for linear trend in sub-optimal adherence with every 100-unit increase in CD4
count at initiation. #Odds ratio for linear trend in sub-optimal adherence with every 5-year increase in age. bOdds ratio for linear trend in sub-
optimal adherence with every month on ART. Distance to the nearest TasP clinic: obtained by measuring the distance as the crow flies from the
participant’s home (GPS coordinates) to the trial clinic (GPS coordinates) in their cluster. Depression (assessed using the Patient Health Question-
naire (PHQ)-4 scale rated as normal (0 to 2), mild (3 to 5), moderate (6 to 8) and severe (9 to 12), [15]. Self-reported health status (as measured
using a scale ranging from 0 to 100% in which 0 represents poor health and 100% represents excellent health). Food insecurity (as measured by
whether skipped meals in last 12 months or not). ART treatment perception (through three questions concerning the participant’s attitudes about
ART).
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evidence of a significant association between CD4 count at
ART initiation and sub-optimal adherence measured by either
VAS or PC during the first 12 months of ART. Adherence
measured by VAS and PC was sub-optimal in 15% and 21% of
visits respectively during the first 12 months of ART. Virologi-
cal suppression was high overall with optimal adherence by
both measures being associated with virological suppression
at 12 months.
We identified only two studies in the African setting, the
first a retrospective and the other a cross-sectional study that
[5,6] assessed risk factors for adherence in individuals who ini-
tiated ART at CD4 count >350 cells/mm3 compared to those
with lower CD4 counts. The retrospective study [5] reported
an association between higher CD4 count at initiation and
adherence <95% whilst the cross-sectional study [6] found no
association between CD4 count at initiation and adherence. In
both studies, the reference group comprised individuals with
advanced HIV disease based on the reported median CD4
count at ART initiation. Our cohort comprised individuals with
a higher median CD4 count at ART initiation than in those
studies and findings corroborate that seen in high income
countries reported in the systematic review by Bock et al.
[18]. WHO recommends universal test and treat for HIV [1];
South Africa has already adopted this recommendation [4] but
there are no data on adherence in people initiating ART at
high CD4 counts (CD4 > 350) in the African setting. With the
new treatment guidelines, the median CD4 count at which
individuals initiate ART is likely to rise to levels observed in
our cohort. However, a meta-analysis covering the period from
January 2002 to Dec 2013 showed that the CD4 count at
presentation for HIV care has increased in South Africa but
the CD4 count at ART initiation has remained unchanged at a
mean of 123 cells/mm3 [18].
One of the WHO’s early warning indicators for develop-
ment of HIV drug resistance is the proportion of pills picked
up on time during the first 12 months of ART which serves as
a proxy for adherence. The proportion of study visits with
optimal adherence during the first 12 months of ART falls just
under the >90% WHO recommendation [19] despite the high
proportion of participants who were virologically suppressed.
Using either adherence measure, men had more than dou-
ble the odds of sub-optimal adherence compared with women,
similar to findings reported in two studies in Tanzania [20]
and South Africa [21]. We observed a high out-migration rate
which was cyclical in nature within the TasP trial. In the popu-
lation adjacent to the TasP communities, a higher outmigration
rate has been reported for men compared to women [22].
This could have contributed to the poorer adherence seen in
men than women in our study. The majority of studies have
reported no sex difference with respect to adherence [23-28],
with one meta-analysis reporting a marginal association of
male sex with higher adherence [17].
Individuals who were on a single tablet ART regimen (fixed
dose combination of tenofovir, emtricitabine and efavirenz) com-
pared to those taking separate tablet regimen (mainly zidovu-
dine, lamivudine and efavirenz) had a lower odds of sub-optimal
adherence. This could be due to the better tolerability profile of
tenofovir-based ART regimen than zidovudine-based ART combi-
nation [7] Furthermore, the once daily tenofovir based ART
combination could have made adherence easier than zidovu-
dine-based ART which had to be taken twice daily.
We found that food insecurity was associated with sub-opti-
mal adherence, similar to findings in Namibia amongst individ-
uals attending a public ART programme [29]. The relationship
between food insecurity and poor adherence has also been
reported in high-income countries [30,31]. Patients who have
missed doses have often cited not having food at home as a
reason for missing doses because of the prevailing perception
that it is bad to take their drugs on an empty stomach. This
anecdotal observation has been confirmed in formal qualita-
tive studies [32,33] and should be discussed when preparing
patients for ART initiation.
Although there is no gold standard measure of adherence
[34], we found both VAS and Pill count adherence to be pre-
dictive of virological suppression. However, there were differ-
ences between both tools. Although we found high agreement
between the two measures, overall adherence as measured by
PC was lower than that of VAS suggesting there is an intrinsic
error associated with the use of each tool [35]. PC adherence
was missing in 30% of visits whilst 23% of visits had missing
VAS adherence. Participants frequently forgot to bring in their
pill bottles, or the health care provider did not take the mea-
sure. Pill count adherence was >105% in 6% of visits; this
apparent “over-adherence” predicted poor virological suppres-
sion so may likely have been owing to participants discarding
pills prior to their clinic appointment [35]. The ease of use of
the VAS would suggest it is preferable in the busy clinical set-
ting of HIV clinics in South Africa and elsewhere. However,
Figure 2. Relationship between mean adherence levels over
12 months measured by visual analogue scale (upper panel) and pill
count (lower panel) and virological suppression at 12 months.
Iwuji C et al. Journal of the International AIDS Society 2018, 21:e25112
http://onlinelibrary.wiley.com/doi/10.1002/jia2.25112/full | https://doi.org/10.1002/jia2.25112
9
unlike with VAS adherence, we found an association between
increased time on ART and increased odds of suboptimal
adherence when using PC adherence in the relatively short
duration of our study. A recent multicentre prospective study
showed that good adherence during the first four months of
ART made undetectable viral load more than three times likely
over a 12 year period [36]. This highlights that adherence sup-
port needs to start as soon as individuals initiate ART and
continue lifelong.
This research study has a few limitations. We included all
individuals who would have been on ART for 12 months by the
time of database closure, rather than restricting our analyses to
only those individuals who remained in the trial for the 12-
month period. This reduces the likelihood of selection bias. The
downside, however, was the large numbers of missing visits
observed as individuals only contributed data for the duration
they were present in the study. If disengagement from care
was related to poor adherence, then we could have overesti-
mated adherence and virological suppression in the trial. We
examined adherence during the first 12 months of ART, hence
our findings cannot be extrapolated to adherence lifelong.
The main strength of our analysis is that it was nested
within a cluster-randomized trial, so that individuals initiated
ART based on the initiation criteria assigned to the cluster in
which they were resident, rather than self-selecting when to
start ART. This could have mitigated against any bias that
might be introduced if individuals choosing to start ART at
higher CD4 counts were more motivated and hence more
likely to adhere. To the best of our knowledge, this is the first
study examining the association between CD4 count at ART
initiation and sub-optimal adherence in individuals initiating
ART at higher CD4 counts in the African Setting.
5 | CONCLUSIONS
We found no evidence of a significant relationship between
CD4 count at ART initiation and sub-optimal adherence during
the first 12 months of ART, using two different measurements
of adherence. With two large trials showing individual health
benefits of initiating ART early [2,3] and the WHO 2015 ART
guidelines recommending HIV treatment regardless of CD4
count [1], a policy already adopted by South Africa [4], this
result should alleviate any concern about adherence in individ-
uals initiating ART at higher CD4 counts, at least during the
first 12 months after ART initiation. This study also provides
much needed evidence on the relationship between adherence
and virologic suppression in this setting and supports the
UNAIDS 90-90-90 target.
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SUPPORTING INFORMATION
Additional Supporting Information may be found online in the
Supporting Information section at the end of the article:
Figure S1. VAS adherence at each visit, among patients with
CD4 count <350 at ART initiation (top-1A) and CD4 count
≥350 (bottom-1B).
Figure S2. Pill count adherence at each visit, among patients
with CD4 count <350 at ART initiation (top-2A) and CD4
count ≥350 (bottom-2B).
Figure S3. Viral suppression and mean adherence over
6 months as measured by VAS (2A) and pill counts (2B).
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